StockNews.com Initiates Coverage on Kamada (NASDAQ:KMDA)

Equities research analysts at StockNews.com assumed coverage on shares of Kamada (NASDAQ:KMDA) in a note issued to investors on Thursday. The firm set a “buy” rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Kamada in a research report on Thursday, May 9th.

Kamada Stock Down 1.7 %

KMDA opened at $4.96 on Thursday. The stock has a market capitalization of $285.10 million, a price-to-earnings ratio of 21.57 and a beta of 1.06. The firm has a 50 day moving average price of $5.27 and a 200-day moving average price of $5.63. Kamada has a twelve month low of $4.08 and a twelve month high of $6.53.

Kamada (NASDAQ:KMDA) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.02). The company had revenue of $37.74 million during the quarter, compared to the consensus estimate of $38.01 million. Kamada had a return on equity of 5.50% and a net margin of 8.33%. As a group, analysts expect that Kamada will post 0.26 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in KMDA. EWA LLC purchased a new stake in shares of Kamada in the 4th quarter worth $68,000. Y.D. More Investments Ltd increased its position in Kamada by 107.1% in the fourth quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock worth $177,000 after buying an additional 15,000 shares in the last quarter. Aristides Capital LLC raised its stake in shares of Kamada by 41.6% in the fourth quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after buying an additional 16,635 shares during the period. Calton & Associates Inc. purchased a new position in shares of Kamada during the 4th quarter valued at about $111,000. Finally, Vanguard Group Inc. grew its stake in shares of Kamada by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after acquiring an additional 100,800 shares during the period. 20.38% of the stock is currently owned by institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.